Genmab and AbbVie Provide Clarification on Phase 3 EPCORE® DLBCL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Go back to Genmab and AbbVie Provide Clarification on Phase 3 EPCORE® DLBCL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)| AbbVie (NYSE: ABBV) | Delayed: 260.32 +3.20 (1.24%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $257.12 | 52 Week High | $68.12 | |||
| Open | $261.67 | 52 Week Low | $50.71 | |||
| Day High | $264.65 | P/E | 56.47 | |||
| Day Low | $260.10 | EPS | $4.61 | |||
| Volume | 830,219 | |||||
| (NASDAQ: GMAB) | Delayed: 32.71 +0.24 (0.74%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $32.47 | 52 Week High | $ | |||
| Open | $32.79 | 52 Week Low | $ | |||
| Day High | $32.96 | P/E | N/A | |||
| Day Low | $32.52 | EPS | $ | |||
| Volume | 347,212 | |||||
